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Abstract
Inherited epidermolysis bullosa (EB) encompasses a number of disorders characterized by recurrent blister formation 
as the result of structural fragility within the skin and selected other tissues. All types and subtypes of EB are rare; the 
overall incidence and prevalence of the disease within the United States is approximately 19 per one million live births 
and 8 per one million population, respectively. Clinical manifestations range widely, from localized blistering of the 
hands and feet to generalized blistering of the skin and oral cavity, and injury to many internal organs. Each EB subtype 
is known to arise from mutations within the genes encoding for several different proteins, each of which is intimately 
involved in the maintenance of keratinocyte structural stability or adhesion of the keratinocyte to the underlying 
dermis. EB is best diagnosed and subclassified by the collective findings obtained via detailed personal and family 
history, in concert with the results of immunofluorescence antigenic mapping, transmission electron microscopy, and 
in some cases, by DNA analysis. Optimal patient management requires a multidisciplinary approach, and revolves 
around the protection of susceptible tissues against trauma, use of sophisticated wound care dressings, aggressive 
nutritional support, and early medical or surgical interventions to correct whenever possible the extracutaneous 
complications. Prognosis varies considerably and is based on both EB subtype and the overall health of the patient.
Disease name: epidermolysis bullosa
Synonyms: see Table 1 and [1]
Definition
Inherited epidermolysis bullosa (EB) encompasses over
30 phenotypically or genotypically distinct entities which
share as a common feature mechanical fragility of epithe-
lial lined or surfaced tissues, most notably the skin [2]. A
characteristic feature of all types of EB is the presence of
recurrent blistering or erosions, the result of even minor
traction to these tissues.
Classification
In general, patients with EB are classified and subclassi-
fied based on the ultrastructural level within which blis-
ters develop within the skin (Table 2), mode of
inheritance, and combinations of clinical, electron micro-
scopic (Table 3), immunohistochemical (Table 4), and
genotypic features. Each of the major EB subtypes is dis-
cussed in great detail in the 2008 consensus report on
diagnosis and classification [3], which was based on the
recommendations of an international panel of EB experts,
superceding two previously recommended classification
schemes [4,5].
There are four major types of inherited EB: EB simplex
(EBS), junctional EB (JEB), dystrophic EB (DEB), and
Kindler syndrome [6]. These differ not only phenotypi-
cally and genotypically but more importantly by the site
of ultrastructural disruption or cleavage. Intraepidermal
blistering is the hallmark feature of EB simplex. EB sim-
plex patients are then further subclassified, based on
whether blisters arise within the basal (i.e., lowermost) or
suprabasal (upper) layers of the epidermis [3]. In contrast,
JEB and DEB patients develop their blisters within the
lamina lucida and sub-lamina densa of the skin basement
membrane zone ("dermoepidermal junction"), respec-
tively. In Kindler syndrome, multiple cleavage planes may
be seen within the same sample of skin [7]. Table 5 lists
each of the major EB types and subtypes, as recognized in
the latest consensus report. As reported in that publica-
tion, the major additions to previous classification
schemes have been (1) the subdivision of EBS patients
into both basal and suprabasal subtypes, to include three
rare mechanobullous disorders having blister formation
within the upper epidermis; (2) the addition of a fourth
major EB type, Kindler syndrome, which had previously
been considered as a poikilodermatous photosensitivity
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ous syndrome (LOC; previously called Shabbir's syn-
drome) [8,9], given its shared molecular target with that
of JEB [10].
Epidemiology
Estimates of prevalence and incidence of EB have been
attempted by different sampling techniques in a number
of populations worldwide, but the most rigorously
obtained ones are derived from the National EB Registry
(NEBR), a cross-sectional and longitudinal epidemiologi-
cal study of EB patients across the entire continental
United States. Over its 16 years (1986-2002) of formal
funding by the National Institutes of Health, nearly 3,300
EB patients were identified, enrolled, classified, clinically
characterized, and followed for outcomes. Among this
robust study population, the prevalence and incidence of
EB was estimated as approximately 8 per one million
population and 19 per one million live births, in 1990 and
1986-1990, respectively [11-13]. These data were then
used to estimate carrier frequencies for EB within the
United States [14]. The NEBR prevalence and incidence
estimates are very similar to most of those reported else-
where (the largest cohort of which is the Italian EB Regis-
try [15]) [16-18], many of which used less rigorous
epidemiological sampling methods. The overall consis-
tency of these data in different parts of the world suggests
that the epidemiological data that have been derived by
the NEBR can indeed be generalized worldwide. Of note,
a greater prevalence of EBS has been reported from Scot-
land [19]. It is unclear whether this reflects possible
greater accessibility of EBS patients for identification and
recruitment in the Scottish Registry or the presence of
some underlying genetic differences which might distin-
guish the Scottish EB population from those in other geo-
graphic regions. For example, the American NEBR data
on EBS are based on the actual findings of the NEBR
study population [11]. Revised estimates of both preva-
lence and incidence in the United States, based on
assumptions of incomplete capture of EBS cases, have
been published in greater detail in the peer-reviewed
monograph which was based on the NEBR database [11].
Given how relatively mild the disease activity usually is in
localized EBS, it is indeed possible that our prevalence
and incidence data on American EBS patients may be an
underestimate if our enrollment of EBS patients had been
discordantly low, although our overall data so closely
match those from Italy that this hypothesis is probably
incorrect.
An important demographic finding among the NEBR
study population was the lack of any EB type or subtype
predilection by gender or ethnicity. In particular, when
Table 1: EB synonyms
Name Synonym(s)
Inherited EB EB hereditaria
EB simplex, localized EB simplex, Weber-Cockayne;
EB simplex of palms and soles
EB simplex, Dowling-Meara EB (simplex) herpetiformis
EB simplex, generalized non-Dowling-Meara EB simplex, Koebner
EB simplex, generalized other
Junctional EB EB atrophicans
JEB, Herlitz JEB generalisata gravis
JEB, non-Herlitz JEB generalisata mitis
Dystrophic EB (DEB) EB dystrophica
Dominant dystrophic EB (DDEB) DDEB, Pasini and Cockayne-Touraine variants
Recessive dystrophic EB (RDEB), severe generalized RDEB, Hallopeau-Siemens;
RDEB generalisata gravis
RDEB, generalized other RDEB, non-Hallopeau-Siemens;
RDEB generalisata mitis
EB with congenital localized atrophy of skin Bart's syndrome
Table 2: Level of blister formation in each major EB type
Major EB Types Level of Blister Formation
EB simplex Intraepidermal
Junctional EB Intra-lamina lucida
Dystrophic EB Sub-lamina densa
Kindler syndrome Multiple levels (intra-lamina lucida and 
sub-lamina densa)
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specialty care within the United States, the overall distri-
bution of NEBR subjects closely resembled that of the
general American population [20].
As anticipated from previous anecdotal experiences
worldwide, the majority of EB patients in the NEBR
cohort had some type of EB simplex [11]. Of these, the
majority had the localized subtype. As also expected, the
majority of patients with generalized junctional EB (JEB)
had the less severe (non-Herlitz) subtype, and the major-
ity of patients with generalized recessive dystrophic EB
(RDEB) had the clinically less severe (non-Hallopeau-Sie-
mens) subtype of this disease.
Clinical description
General considerations [2]
The hallmark cutaneous features of inherited EB, in addi-
tion to mechanically fragile skin and easy inducibility of
blisters (Figure 1) or erosions, include some or all of the
following: milia (tiny firm white papules, resembling cysts
or pustules) (Figure 2), nail dystrophy or absence, and
scarring (usually atrophic). Additionally useful findings, if
present, include exuberant granulation tissue (periorifi-
cial; axillary vaults; nape of the neck; lumbosacral spine;
periungual and proximal nail folds), localized or conflu-
ent keratoderma of the palms and soles, and dyspigmen-
tation (postinflammatory hypo- or hyperpigmentation;
mottled or reticulate hyperpigmentation). Infrequently
seen and extremely nonspecific cutaneous findings
include decreased or absent hair, albopapuloid lesions
(flesh-colored or hypopigmented papules, usually arising
on the lower trunk), and hypo- or hyperhidrosis [21].
Several factors must be considered when attempting to
use cutaneous findings as surrogate diagnostic markers.
First, the presence or absence of one or more findings
may be age-dependent [22]. That is, not all of these skin
findings are necessarily seen in neonates or infants. For
example, scarring, nail dystrophy, milia, and exuberant
granulation tissue may develop only after several months
or even years of life. As such, their absence cannot be reli-
ably used for diagnosis during that window of time (i.e.,
early infancy) when classification and subclassification
are most needed [22]. Similarly, exuberant granulation
tissue, the most pathognomonic skin finding in EB, which
Table 3: Transmission electron microscopy findings among selected EB subtypes
EB type Major EB subtype Level of cleavage Associated ultrastructural findings
EB simplex (suprabasal) EB simplex superficialis subcorneal ---
lethal acantholytic EB suprabasal acantholysis; perinuclear retraction of keratin 
filaments
EBS, plakophilin deficiency mid-epidermis perinuclear retraction of keratin filaments; 
small suprabasal desmosomes
EBS (basal) EBS, localized basal keratinocyte ---
EBS, Dowling-Meara basal keratinocyte clumped keratin filaments
EBS, generalized other basal keratinocyte ---
EBS, autosomal recessive basal keratinocyte absent or reduced keratin filaments within 
basal keratinocytes
Junctional EB JEB, Herlitz intra-lamina lucida markedly reduced or absent 
hemidesmosomes; absent subbasal dense 
plates; absent anchoring filaments
JEB, non-Herlitz intra-lamina lucida hemidesmosomes may be normal or reduced 
in size and number
JEB with pyloric atresia intra-lamina lucida small hemidesmosome plaques with 
attenuated subbasal dense plates
Dominant dystrophic EB DDEB, generalized sub-lamina densa normal or reduced numbers of anchoring 
fibrils
DDEB, bullous dermolysis of the newborn sub-lamina densa electron-dense stellate shaped bodies within 
basal keratinocytes; reduced numbers of 
anchoring fibrils
Recessive dystrophic EB RDEB, severe generalized sub-lamina densa absent or rudimentary appearing anchoring 
fibrils
RDEB, generalized other (generalized mitis) sub-lamina densa reduced or rudimentary appearing anchoring 
fibrils
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alized JEB, may completely resolve spontaneously in rare
patients during adulthood. Second, some findings (such
as albopapuloid lesions or aplasia cutis) may arise in more
than one EB type or subtype, making them insufficiently
specific to be reliably used as diagnostic tools [21].
Indeed, when sensitivity and specificity analyses were
performed on the robust database of the NEBR, the only
cutaneous finding reaching 90% in both sensitivity and
specificity as a surrogate diagnostic marker (even when
up to three findings were considered in combination) was
exuberant granulation tissue, emphasizing the inherent
risks associated with relying too heavily solely on the
presence or absence of EB-associated skin findings [22].
All types and subtypes of inherited EB are associated
with mechanically fragile skin. This can be induced by
light lateral or rotary traction to the skin. In general, skin
from patients with JEB and RDEB is much more fragile
than that of EBS patients. Although most EB patients
usually present with intact blisters, erosions may instead
be the overriding finding in patients having one of the
more superficial (i.e., suprabasal) EBS subtypes [3]. Skin
fragility in EB is characteristically worsened in warm
weather or warm living environments; hence the value of
air-conditioning for families with affected children. The
one exception to this observation, which is seen in only a
subset of EBS-DM patients, is a temporary reduction of
blistering during periods of high fever. Of practical
importance, a history of seasonally dependent (i.e., sum-
mertime) blistering is more often elicited in EB patients
having milder or more localized types or subtypes of the
disease, especially those with EBS, since the most severely
affected patients (particularly those with generalized JEB
and RDEB) have such continuous generalized blistering
that any influence by temperature is clinically negligible.
Potentially any extracutaneous tissue which is lined or
surfaced by epithelium may be injured in EB [23-25]. In
general, the more severe and widely distributed the blis-
tering on the skin is, the more likely it is for multiple
extracutaneous sites to also become involved. As is the
case with cutaneous findings, these extracutaneous com-
plications are also age-dependent, with time of onset and
cumulative risk of occurrence highly dependent on the
EB subtype that is present. Examples of the cumulative
risks for the most important extracutaneous complica-
tions will be reviewed in detail elsewhere in the context of
specific EB subtypes. As will also be discussed subse-
quently, other non-epithelial organs or tissues may also
Table 4: Diagnostically useful differences in antigenic staining in selected EB subtypes
Common antigens Abnormal staining in Typical pattern of staining
Keratin 5 --- normal filamentous network within 
keratinocytes
Keratin 14 EBS, autosomal recessive absent or markedly reduced staining of 
filaments within keratinocytes
Laminin-332 (laminin-5) JEB-H absent or markedly reduced staining along 
the DEJ
JEB-nH * reduced staining along the DEJ
Type XVII collagen JEB-nH * reduced or absent staining along the DEJ
Type VII collagen RDEB, severe generalized usually absent staining along the DEJ
RDEB, generalized other reduced staining along the DEJ
RDEB, inversa variable staining along the DEJ
Dystrophic EB-BDN (only during periods of active blistering) granular staining within basal and lower 
suprabasal keratinocytes; absent or markedly 
reduced staining along the DEJ
Plectin EBS with muscular dystrophy; EBS with pyloric atresia; EBS-Ogna absent or reduced staining along the DEJ; 
absent or reduced staining along the DEJ; 
reduced staining along the DEJ
α6β4 integrin JEB with pyloric atresia; EBS with pyloric atresia absent or reduced staining along the DEJ; 
absent or reduced staining along the DEJ
Kindlin-1 Kindler syndrome absent or reduced staining along the DEJ
DEJ = dermoepidermal junction
* The majority of patients with JEB-nH have mutations in one of the three genes encoding for laminin-332, rather than within the gene for 
type XVII collagen. Of note, there are usually no phenotypic differences in these two antigenically distinct JEB-nH groups.
Modified from Fine J-D et al, 2008 (reference [3]); refer to that reference for less frequent findings
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Table 5: Major EB subtypes and their targeted proteins (per the 2008 international consensus report )
Major EB Type Major EB Subtypes Targeted Protein(s)
EB simplex (EBS) suprabasal subtypes
lethal acantholytic EBS desmoplakin
plakophilin-1 deficiency plakophilin-1
EBS superficialis (EBSS) ?
basal subtypes
EBS, localized (EBS-loc) K5, K14
EBS, Dowling-Meara (EBS-DM) K5, K14
EBS, other generalized (EBS,-gen nDM) K5, K14
EBS with mottled pigmentation (EBS-MP) K5
EBS with muscular dystrophy (EBS-MD) plectin
EBS with pyloric atresia (EBS-PA) plectin; α6β4 integrin
EBS, autosomal recessive (EBS-AR) K14
EBS, Ogna (EBS-Og) plectin
EBS, migratory circinate (EBS-migr) K5
Junctional EB (JEB) JEB, Herlitz (JEB-H) laminin-332
JEB, generalized non-Herlitz (JEB-nH gen) laminin-332; type XVII collagen
JEB, localized non-Herlitz (JEB-nH loc) type XVII collagen
JEB with pyloric atresia (JEB-PA) α6β4 integrin
JEB, inversa (JEB-I) laminin-332
JEB, late onset (JEB-lo) ?
LOC syndrome laminin-332 α3 chain
Dominant dystrophic EB (DDEB) DDEB, generalized (DDEB-gen) type VII collagen
DDEB, acral (DDEB-ac) type VII collagen
DDEB, pretibial (DDEB-Pt) type VII collagen
DDEB, pruriginosa (DDEB-Pr) type VII collagen
DDEB, nails only (DDEB-na) type VII collagen
DDEB, bullous dermolysis of newborn (DDEB-BDN) type VII collagen
Recessive dystrophic EB (RDEB) RDEB, severe generalized (RDEB-sev gen) type VII collagen
RDEB, generalized other (RDEB, generalized mitis (RDEB-O) type VII collagen
RDEB, inversa (RDEB-I) type VII collagen
RDEB, pretibial (RDEB-Pt) type VII collagen
RDEB, pruriginosa (RDEB-Pr) type VII collagen
RDEB, centripetalis (RDEB-Ce) type VII collagen
RDEB, bullous dermolysis of newborn (RDEB-BDN) type VII collagen
Kindler syndrome kindlin-1
Modified from Fine JD et al (reference [3])
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hypoplasia [26] is seen exclusively in all subtypes of JEB
(and is therefore a highly useful diagnostic finding), and
muscular dystrophy (either congenital or late onset) may
accompany one specific subtype of EBS. Some other
organs, for example, the heart and kidney, may also
become secondarily injured in severely affected EB
patients.
When counseling a family with an affected child, it is
important to realize that considerable variability in the
frequency and severity of extracutaneous complications
may be seen within not only a single major EB subtype
but even within a kindred. The risk and time of onset of
occurrence of these complications may vary considerably
from one EB subtype to another. Some EB types and sub-
types are particularly at risk for premature death from
one or more causes. Finally, genotype-phenotype correla-
tion, with the exception of EBS, is rather weak [3].
EB simplex
As discussed in much greater detail within the 2008 con-
sensus report [3], there is a wide range of cutaneous find-
ings among the many EBS subtypes. With only three rare
exceptions (Table 5), blisters arise within the basal layer
of the epidermis in patients with EBS. Onset of disease
activity in EBS is usually at or shortly after birth, although
patients with localized EBS may not develop blistering
until late childhood or even early adulthood. As a general
rule, far less scarring, milia formation, and nail dystrophy
are seen in EBS, as compared to JEB and DEB, although
even the combination of all three of these clinical find-
ings, when used as a diagnostic test to distinguish EBS
from all other EB types, failed to provide both sensitivity
and specificity of > 90% [21].
The most common type of EB, as well as the most com-
mon subtype of EBS, is localized EBS, formerly known as
Weber-Cockayne disease. Among the National EB Regis-
try population, half of all participants had EBS; of these,
two-thirds had localized EBS [20]. The usual distribution
of blisters in these patients is on the palms and soles (Fig-
ure 3), although any other skin surface may also blister if
sufficiently traumatized. Milia, scarring, and nail dystro-
phy are uncommon to rare skin findings in all forms of
EBS, with the lowest frequency noted in localized EBS.
The only common extracutaneous finding in localized
EBS, localized intraoral erosions or blisters, tends to be
asymptomatic, occurs in about one-third of these
patients, and usually is seen only during infancy [27,28].
There are several subtypes of more generalized EBS.
The most noteworthy one, EBS-Dowling Meara (DM)
[29], is frequently associated with marked morbidity and,
in a minority of patients, may result in death during early
infancy. Its hallmark feature is the presence of intact vesi-
cles or small blisters in grouped or arcuate configuration
(Figure 4). Such herpes simplex-like clustering of lesions
explains why this entity was originally named EB herpeti-
formis, although there is no true association between this
disease and either herpetic infection or the autoimmune
bullous disease, dermatitis herpetiformis. By late child-
hood, most patients with EBS-DM develop confluent
thickening and hyperkeratosis ("keratoderma") of the
palms and soles which may partially resolve in some
patients during mid- to late-adulthood. Although not a
universal finding, some patients with EBS-DM may
Figure 1 A typical noninflammatory blister arising in the skin of a 
patient with EB.
Figure 2 Milia arising within an erythematous patch on the knee 
of a patient with DDEB.
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weather exacerbates disease activity in all EB patients.
The reason for such a phenomenon is unknown. The
most notable extracutaneous complication in EBS, and
one that is seen in only rare patients with EBS-DM, is tra-
cheolaryngeal compromise, mimicking that which arises
in both major subtypes of JEB [30,31]. There is also a
markedly increased risk of developing basal cell carcino-
mas by mid-adulthood (cumulative risk of 44% by age 55)
[32], a finding seen in EB only among patients with EBS-
DM.
Another subtype of generalized EBS ("EBS generalized
other" or non-Dowling-Meara generalized EBS), formerly
named EBS-Koebner (EBS-K), is characterized by non-
herpetiform blisters and erosions arising on any skin sur-
face [33]. Of note, these blisters tend to spare the palms
and soles, distinguishing them from patients with local-
ized EBS. The frequency of milia, scarring, and nail dys-
trophy is intermediate between that of localized EBS and
EBS-DM, and extracutaneous findings, other than occa-
sional intraoral blistering, are rare. Given the consider-
able overlap between EBS-K and localized EBS within
some kindreds, some experts prefer to group both sub-
types together.
Other clinically striking but rare basal EB subtypes
include EBS with mottled pigmentation (EBS-MP)
[34,35], EBS with muscular dystrophy (EBS-MD) [36,37],
autosomal recessive EBS [38], EBS with circinate migra-
tory blistering [39], and EBS-Ogna [40,41], the latter of
which is associated with easy bruisability, hemorrhagic
blistering, and marked nail deformity (onychogryphosis)
[3]. From a prognostic point of view, immunohistochemi-
cal recognition of EBS-MD in infancy is particularly
important, since in some patients the associated muscu-
lar dystrophy may not become apparent until later in
childhood or early adulthood.
Junctional EB
There is only one clinical finding that is characteristic of
all subtypes of JEB -- the presence of enamel hypoplasia,
manifested as localized or more extensive thimble-like
pitting of some or all of the tooth surfaces (Figure 5)
[26,42]. It is therefore an extremely useful clinical finding,
although it cannot be used as a diagnostic tool until after
the primary teeth have erupted.
There are two major JEB subtypes. The more severe
one, JEB-Herlitz (JEB-H), is present at birth and involves
all skin surfaces [43]. Approximately 20% of all JEB
patients within the United States have this phenotype
[11]. An essentially pathognomonic finding is exuberant
granulation tissue (Figure 6), which usually arises within
the first several months to one to two years of life. This
may involve not only the skin but also the upper airway.
Moderate to severe intraoral blistering is invariably pres-
ent, with some eventual narrowing of the opening of the
mouth ("microstomia") and reduced extension of the
tongue ("ankyloglossia"), although these findings are not
as pronounced as is observed in severe generalized RDEB
[27]. Rather profound growth retardation and multifacto-
rial anemia are the norms in JEB-H [25]. Many other
organs may be involved, including but not restricted to
the esophagus (strictures) [44], external eye (corneal blis-
ters, erosions, and scarring; ectropion formation) [45],
Figure 3 The blistered foot of an infant with localized EBS.
Figure 4 Circinate grouping of blisters arising on the skin of a pa-
tient with the Dowling-Meara variant of generalized EBS.
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urinary tract [46]. Among JEB-H children, for example,
the cumulative risk of laryngeal stenosis or stricture is
40% by age 6 [30]. The highest risk of infant mortality
among EB neonates, infants, and young children occurs
in JEB-H, and is most often the result of sepsis, failure to
thrive, or tracheolaryngeal obstruction (the latter usually
secondary to severe progressive airway stenosis within or
above the level of the vocal cords) [47]. Indeed, as of Janu-
ary 1, 2002, over half of all JEB-H patients enrolled in the
NEBR had died within the first two years of life.
Squamous cell carcinomas may also arise in a minority of
JEB-H patients (cumulative risk of 18% by age 25) [32].
The most common JEB subtype, comprising nearly 80%
of the American JEB population, is non-Herlitz JEB (JEB-
nH), a generalized disorder characterized by the presence
of blistering, atrophic scarring, and nail dystrophy or
absence. It, too, is usually clinically apparent at birth.
Postinflammatory hypopigmentation or depigmentation
may be striking in some JEB-nH patients. A prominent
feature described among the original Tyrolean kindred
was scarring alopecia of the scalp [48], although experi-
ence in other populations has shown that this is not a uni-
versal finding among JEB-nH patients. The cumulative
risk of upper airway occlusion in JEB-nH (13% by age 9) is
lower than that observed in JEB-H [30] although the risk
of death among those JEB-nH patients with this compli-
cation is essentially the same. The frequencies of other
extracutaneous complications, including severe anemia
and growth retardation, however, are far lower among
JEB-nH than JEB-H patients, as is the risk of premature
death from non-airway-related complications [47].
A rare but clinically important JEB subtype, inverse JEB,
is associated with rather severe blistering and erosions
confined to intertriginous skin sites, esophagus, and
vagina [3].
JEB with pyloric atresia presents with generalized blis-
tering at birth and congenital atresia of the pylorus (and
rarely of other portions of the gastrointestinal tract)
[3,49]. This latter disorder is associated with a significant
risk of congenital anomalies of the genitourinary tract
and infantile or neonatal death. It should be noted that
rare patients with identical phenotypes have been shown
to have intraepidermal rather than intra-lamina lucida
blister formation, necessitating their inclusion among the
rarer subtypes of EBS rather than JEB.
The LOC syndrome is characterized by localized blis-
tering and scarring, particularly on the face and neck, in
association with upper airway disease activity and nail
abnormalities [8,9]. Characteristic cutaneous findings are
erosions and granulation tissue. The conjunctiva is
involved and enamel hypoplasia is present.
Dystrophic EB
Dystrophic EB (DEB) is separated into two major types,
based on the mode of transmission (autosomal dominant
versus autosomal recessive). As noted in Table 5, DEB
patients are further subdivided by clinical phenotype and
severity of disease [3].
Dominant dystrophic EB
By convention, all patients with generalized dominant
DEB (DDEB) are now grouped together. Although, in the
past, two DDEB subtypes, Pasini [50] and Cockayne-Tou-
raine DDEB [51], were considered to be different dis-
eases, more recent studies have failed to confirm either
the specificity of albopapuloid lesions or differences in
genotype between these two putatively distinct DDEB
subtypes [3]. The prototypic DDEB patient has general-
ized blistering at birth which, with time, is associated
with mila, atrophic (or less commonly, hypertrophic)
scarring (Figures 7 and 8), and nail dystrophy (Figure 9).
Recurrent esophageal blistering and erosions, leading to
progressive dysphagia secondary to esophageal stricture
formation, is common among these patients [44]. In con-
trast to severe generalized RDEB and JEB-H, however,
Figure 5 Rather profound enamel pitting in a patient with JEB.
Figure 6 Exuberant granulation tissue arising on the nape of the 
neck of a child with Herlitz JEB.
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infant mortality, and risk of squamous cell carcinoma are
not characteristic features of DDEB [24,25,47].
There are a number of less common DDEB subtypes, as
listed in Table 5. A rare localized variant, acral DDEB, is
characterized by cutaneous involvement confined pri-
marily to the hands and feet. Of note, pseudosyndactyly is
not a feature of this entity.
Pretibial DDEB, as the name implies, almost exclusively
involves the anterior lower legs [52,53]. Individual
lesions, which tend to be papular or plaque-like, are
oftentimes somewhat violaceous, suggesting the clinical
diagnosis of lichen planus. Bullae and scarring are also
present. Dystrophy of both fingernails and toenails is
characteristic; in contrast to lichen planus, these nail
changes do not include pterygium formation.
DDEB pruriginosa is a more generalized subtype of
DDEB which is characterized by severe, if not intractable,
pruritus [54]. Bullous dermolysis of the newborn (BDN) is
a subtype of dystrophic EB which is usually transmitted in
an autosomal dominant manner [55]. It, like other gener-
alized forms of EB, presents at or shortly after birth and
may be accompanied by focal atrophic scarring. In con-
trast to all other types and subtypes of EB, disease activity
usually ceases within the first 6 to 24 months of life.
A rare finding associated with EB and arising on one or
more extremities, congenital localized absence of skin
(CLAS) (Figure 10), was originally observed within a
large kindred with autosomal dominant transmission of
blistering; this family was later proven to have DDEB
[56,57]. Referred to as Bart's syndrome and once believed
to be a distinct entity, it is now known that CLAS may
arise in EBS, JEB, and RDEB, as well as in DDEB. As such,
the eponym is no longer used and the condition is no lon-
ger deemed to be a separate EB subtype [5].
Recessive dystrophic EB
There are three main subtypes of RDEB -- severe general-
ized RDEB (formerly named Hallopeau-Siemens RDEB),
non-Hallopeau-Siemens RDEB, and inverse RDEB. Each
has its onset at birth. The most severe subtype, severe
generalized RDEB, is clearly one of the most devastating
multiorgan genetically transmitted diseases of mankind.
Prototypic findings include generalized blistering at birth,
progressive and oftentimes mutilating scarring of the
skin, corneal blisters or scarring [45], profound growth
retardation [44], multifactorial anemia, failure to thrive
(less common than in JEB-H), esophageal strictures [44],
and debilitating hand and foot deformities ("mitten defor-
mities"; pseudosyndactyly) (Figures 11 and 12) [58]. Two
Figure 7 Atrophic scarring and postinflammatory hypopigmen-
tation on the extremity of a patient with DDEB.
Figure 8 Hypertrophic scarring in a patient with generalized 
DDEB.
Figure 9 Dystrophy of all twenty nails in a patient with DDEB.
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tures and pseudosyndactyly, are of particular importance,
since they occur early in childhood and continue to nega-
tively impact on the functionality of these patients
throughout life. About 10% and 90% of all of these
patients will develop symptomatic esophageal stricturing
by ages 2 and 35, respectively [44]. Similarly, about 30% of
severe generalized RDEB patients have signs of pseudo-
syndactyly as early as 2 years of age and virtually 100%
will have developed this by age 20 [58].
Severe ankyloglossia and microstomia are the norm in
severe generalized RDEB, and contribute to the markedly
impaired oral intake of solid foods. Although secondary
caries occur, no primary enamel defects exist in any type
or subtype of dystrophic EB.
Chronic renal failure, the result of poststreptococcal
glomerulonephritis or renal amyloidosis, occurs within
this RDEB subtype, and may eventually lead to death in
about 12% [59]. A low but real risk of potentially fatal
dilated cardiomyopathy (4.5% cumulative risk by age 20,
30% of whom eventually die of this complication) exists in
patients with severe generalized RDEB. Although the
cause is unproven, data suggest the possibility that this
may result from a micronutrient deficiency (carnitine;
selenium) or chronic iron overload [60].
Although the risk of infantile death from any cause is
low in RDEB, nearly all patients with severe generalized
RDEB will develop at least one cutaneous squamous cell
carcinoma (arising as early as within the second decade of
life), and most (about 87% by age 45) will then die of met-
astatic squamous cell carcinoma within five years of the
time of diagnosis of the first squamous cell carcinoma,
despite apparent complete surgical removal of each pri-
mary carcinoma [32]. Rare children with severe general-
ized RDEB are also at risk of developing malignant
melanoma (cumulative risk of 2.5% by age 12) although
none of the latter has resulted in metastasis [32].
A more common RDEB subtype, formerly known as
non-Hallopeau-Siemens RDEB (and probably best
referred to as generalized mitis RDEB), has similar but
less severe cutaneous involvement and a much lower risk
of esophageal strictures, corneal injury, or hand or foot
deformities. Growth retardation and anemia are
extremely uncommon. However, these patients still have
a significant risk of developing squamous cell carcinomas
(47.5% by age 65), although the risk of death from metas-
tases (60% by age 65) is lower than that which is seen in
severe generalized RDEB [32].
A rare subtype of RDEB, inverse RDEB, is characterized
by blistering and erosions which are primarily confined to
Figure 10 Congenital absence of skin on the leg of a neonate with 
Bart's syndrome.
Figure 11 Partial mitten deformity of the hand of a child with se-
vere generalized RDEB.
Figure 12 Complete mutilating deformities of the hands of a 
young adult with severe generalized RDEB.
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most back, and the lumbosacral area. Patients with this
subtype are particularly prone to develop severe blister-
ing within the oral cavity, esophagus, and the lowermost
portion of the genitourinary tract. Debilitating strictures
may eventually develop within the esophagus (cumulative
risks of 10% and 90% by ages 5 and 30, respectively) [44]
and vagina. These strictures may be extremely severe,
markedly impairing intake of nutrients and normal sexual
functionality. Although squamous cell carcinomas may
also arise in these patients, the cumulative risk (23% by
age 45) is much lower than that which is seen in either of
the two generalized subtypes of RDEB [32].
Bullous dermolysis of the newborn may rarely be trans-
mitted as a severe autosomal recessive disease. In the set-
ting of this mode of transmission, it may prove fatal
within early infancy. Other rare RDEB subtypes include
pretibial RDEB, RDEB pruriginosa, and RDEB centripeta-
lis [61], the latter of which is characterized by cutaneous
disease activity which begins acrally and then progres-
sively spreads toward the trunk over decades.
Kindler syndrome
Kindler syndrome is characterized by generalized blister-
ing at birth and the later development of characteristic
poikilodermatous pigmentation and photosensitivity.
Skin findings may include atrophic scarring and nail dys-
trophy, at times closely mimicking JEB-nH. Extracutane-
ous complications may include severe colitis, esophagitis,
urethral strictures and, rarely, ectropions [3]. Teeth are
uninvolved but gingival hyperplasia may develop. Skin
derived squamous cell carcinomas have been reported in
at least two of these patients.
Etiopathogenesis [3]
Genetics
Inherited EB is transmitted as either an autosomal domi-
nant or autosomal recessive disease, depending on EB
type and subtype. As noted elsewhere, most EB pheno-
types have only one mode of genetic transmission. Of
importance, spontaneous mutations for autosomal domi-
nant disease are not uncommon in EBS but account for
only the minority of cases of DEB lacking a known family
history for the disease. Incomplete penetrance has been
documented only rarely in autosomal dominant EB kin-
dreds.
Molecular basis of disease
Inherited EB has been shown to result from mutations in
any of several structural proteins normally present within
the keratinocyte or the skin basement membrane zone
("dermoepidermal junction") [3]. In general, the severity
of skin and extracutaneous disease is a reflection of the
type of mutation which is present, as well as the ultra-
structural location of the targeted protein. Localized EBS,
EBS-DM, and EBS generalized other (EBS-Koebner)
result from dominant negative mutations within either
the keratin 5 or keratin 14 gene. The site of mutation --
i.e., the location within the individual keratin filament --
is strongly correlated with EBS subtype, with EBS-DM
patients having mutations within particularly structurally
sensitive portions of the molecule. EBS with mottled pig-
mentation results from mutations within the keratin 5
gene, and EBS with muscular dystrophy is caused by
mutations within the gene for plectin. A rare autosomal
recessive form of EBS is known to result from mutations
in the keratin 14 gene. EBS with pyloric atresia is caused
by mutations either within the gene for plectin or the
genes for the heterodimeric transmembrane protein,
α6β4 integrin. Two suprabasal subtypes of EBS -- plako-
philin deficiency [62] and lethal acantholytic EB [63] --
are known to arise as the result of mutations in the genes
for plakophilin-1 and desmoplakin, respectively. The
molecular etiology of EBS superficialis (EBSS) is still
unclear although one family previously diagnosed with
this was later shown to have a type VII collagen mutation
similar to those seen in DDEB [64]. In support of EBSS
being a distinctive entity, however, is the lack of any
detectable type VII collagen mutation in the original pub-
lished proband (unpublished data, 2009).
JEB-H results from severe mutations within any of the
three genes which encode for the three-chained adhesion
molecule, laminin-332 (previously named laminin-5).
The presence of mutational hotspots with this disease
facilitates rapid DNA screening in many patients. The
majority of JEB-nH patients have less severe mutations
within the same targeted genes, although a minority have
mutations instead within the gene encoding for type XVII
collagen (formerly known as bullous pemphigoid antigen
2 or BP-180). JEB with pyloric atresia is caused by muta-
tions in either of the genes encoding for the two subunits
of α6β4 integrin [65-67].
All types of DEB result from mutations within the type
VII collagen gene (COL7A1) [68]. Of note, those with
DDEB tend to have missense mutations resulting in gly-
cine substitutions within the triple helical domain of type
VII collagen. Analogous to what is seen in JEB-H and
JEB-nH, patients with severe generalized RDEB may be
either homozygous for their COL7A1 mutation or have
two different mutations (i.e., "compound heterozygos-
ity"), resulting in premature termination codons. In con-
trast, less severe types of mutations within the type VII
collagen gene occur in patients with RDEB generalized
other. In contrast to JEB, there are no mutational
hotspots within the COL7A1 gene, so nearly every DEB
family has its own unique site and/or type of mutation. A
detailed summary of these mutations has been recently
published [3].
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matosis, is caused by mutations in the gene for kindlin-1,




Each major EB type is diagnosed by determination of the
ultrastructural level within which blisters develop follow-
ing minor traction to the skin (Table 2). Subtypes are then
defined on the basis of mode of transmission, immuno-
histochemical and electron microscopic findings, and
clinical phenotype. Detailed summaries of the phenotypic
features of each EB subtype have been recently published




In the absence of a well characterized proband within the
same kindred, every patient suspected of having inherited
EB should have one or more skin specimens harvested
and properly processed for diagnostic immunofluores-
cence antigenic mapping (IAM) and transmission elec-
tron microscopy (TEM) [22]. The precise ultrastructural
level of mechanical fragility and inducible blister forma-
tion can be ascertained by one or both of these diagnostic
techniques. Details as to optimal harvesting of specimens
and the transport solutions needed have been reviewed
elsewhere [3,22]. In general, though, the best samples for
IAM and TEM are small punch biopsies and shave biop-
sies, respectively, harvested from nonblistered skin which
has been first subjected to mild rotary traction. The con-
ventional inclusion of EB-relevant antibodies as part of
the IAM study may allow further subclassification of
these patients, based on the location, pattern, and relative
intensity of staining by one or more of these antibodies.
However, there is still sufficient overlap across some EB
subtypes as to limit precise subclassification on every
case based solely on these immunohistochemical findings
even when additional monoclonal antibodies are
employed [22,70,71]. TEM also permits the direct semi-
quantification of specific ultrastructural structures (i.e.,
keratin filaments; hemidesmosomes; anchoring fibrils;
subbasal dense plates). These findings can be helpful in
subclassifying some cases. Of importance, when IAM
and TEM results were compared on matched specimens
harvested from a large number of consecutively biopsied
EB patients, neither technique was proven to be more
accurate, with a discordancy rate of only about 3%, sug-
gesting that either technique, when properly processed
and interpreted, will be equally informative diagnostically
[22,72]. Given the technical difficulties associated with
processing and interpreting EB specimens by these two
techniques, non-molecular diagnostic studies on EB
specimens are best done by a limited number of diagnos-
tic reference laboratories having extensive experience in
EB. A list of recommended laboratories may be found in
the 2008 consensus report [3].
It is important to stress that routine histological pro-
cessing of skin is not recommended in the setting of EB,
since it may be difficult or impossible to distinguish at the
light microscopy level between even lower intraepider-
mal and subepidermal cleavage in some specimens. Simi-
larly, the precise distinction between intra-lamina lucida
(i.e., JEB) and sub-lamina densa (i.e., DEB) cleavage can
be ascertained only by IAM or TEM. As a further reason
for not pursuing routine histology, most of the EB-rele-
vant antibodies used in IAM cannot be employed on con-
ventional formalin-preserved tissue samples, due to loss
of antigenicity in the latter tissues. Alternatively, attempts
at using these paraffin embedded tissue blocks for subse-
quent TEM evaluation are also invariably suboptimal,
due to differences in the fixatives used for tissue preser-
vation.
As discussed in the 2008 consensus report, DNA muta-
tional analysis for subclassification of EB is still primarily
reserved for prenatal diagnosis (and even then only when
the causative mutation has already been identified in a
proband within the same family), or when preimplanta-
tion therapy is being considered, given the considerable
problems that have been seen with genotype-phenotype
correlation within most of the EB subtypes [3]. In addi-
tion, DNA testing is not routinely performed in the
absence of prior tissue confirmation of the major type of
EB which is present, since there are too many genes
potentially involved in EB to make simultaneous screen-
ing of multiple genes either practical or affordable. If and
when gene replacement therapy becomes a reality, then
DNA mutational analysis will become part of the work-
up of all patients. Until that time, there may be other rea-
sons to pursue DNA mutational analysis in selected cases.
These include determination of the mode of transmission
in patients suspected of having spontaneous mutations
for DDEB (since the majority of these have been shown to
have RDEB instead) or in patients involved in specific
research projects which might benefit from full genotypic
determination. Some families having one or more
severely affected family members with autosomal reces-
sive disease may also desire to screen clinically unaffected
siblings for possible silent mutations, as well as their
genetically unrelated spouses, prior to their pursuing
pregnancy. Given how low the prevalence of autosomal
recessive types of EB is within the general population,
however, the likelihood of affected offspring arising from
such pregnancies is extraordinarily low, making this very
cost-ineffective.
Fine Orphanet Journal of Rare Diseases 2010, 5:12
http://www.ojrd.com/content/5/1/12
Page 13 of 17Prenatal diagnosis
Through the early 1990 s, prenatal diagnosis was rou-
tinely performed via either IAM or TEM on fetal skin
specimens that were harvested, via ultrasound-directed
fetoscopic sampling techniques, on or after about the 17
th gestational week [73,74]. Since the mid-1900 s, DNA
mutational analysis has become the standard of care,
using specimens obtained from chorionic villi, with the
caveats noted above.
Differential diagnosis
The size and validity of the differential diagnosis gener-
ated on a child or adult with blistering of the skin is truly
a reflection of the level of training and expertise of the
physician. Indeed, in most situations the diagnosis of
inherited EB should be obvious to a dermatologist; in
only a minority of cases will there be any need for a more
extensive differential diagnosis to be entertained prior to
tissue confirmation. In the neonatal period, however, in
utero herpes simplex infection might need be considered,
especially if there is no family history of a blistering dis-
ease or if the clinical findings are very atypical for EB.
Other conditions that may be considered as part of the
differential diagnosis of EB are summarized in Table 6[3].
Genetic counseling [75]
Genetic counseling is best performed either by a medical
geneticist or a dermatologist who has considerable expe-
rience with EB. Ultimately the diagnosis will be based on
clinical phenotype, mode of transmission, IAM, TEM,
and, when available, the mutational analysis of the
affected proband. In-depth recommendations on the
counseling of EB patients and their families have been
recently published [75].
Management
The basic underlying tenets of care for all EB patients are
avoidance of blistering (by meticulous protective padding
of the skin) and prevention of secondary infection (by
careful wound care, facilitated by the use of sterile syn-
thetic non-adhesive hydrocolloid dressings). Patients
with EB subtypes known to be at highest risk for specific
extracutaneous complications need careful surveillance
[76] for their occurrence, and implementation of appro-
priate interventions (medical; surgical; dental; nutri-
tional; psychological; other) prior to the affected tissues
becoming severely injured [24,25,76]. For example, early
signs and symptoms of corneal disease activity need
prompt evaluation by an ophthalmologist so as to prevent
the development of permanent corneal scarring and
impaired vision. Symptomatic esophageal strictures need
to be dilated, oftentimes repeatedly, in order to maintain
adequate intake of nutrients by mouth. Those children
unable to take in sufficient nutrients by mouth are instead
given nutrient supplements via gastrostomy [77]. Hand
deformities, if they cannot be prevented by meticulous
nightly wrapping of the digits, may be temporarily
improved by surgical degloving procedures. Squamous
cell carcinomas, which may arise as early as the second
decade of life in patients with severe generalized RDEB
and JEB-H, are treated by conventional wide excision,
with careful follow-up to monitor for local or regional
recurrence. Patients with generalized forms of JEB and
RDEB need to be monitored by serial DEXA scans for
possible osteoporosis or osteopenia, and in selected EB
subsets other laboratory parameters (hematological;
renal) or diagnostic tests (echocardiogram) should also
be serially monitored or performed.
Several experimental approaches are now being
explored for possible therapeutic use. These include, for
autosomal recessive types of EB, ex vivo gene replace-
ment [78,79], transplantation of allogeneic fibroblasts (in
RDEB, to provide a source of normal type VII collagen)
[80,81], transplantation of bone marrow-derived stem
cells [82], and infusion of recombinant protein (i.e., type
VII collagen for RDEB) [83]. For autosomal dominantly
transmitted EB, a variety of studies are being pursued
which are focused on means that possibly might either
downregulate the dominant negative gene or, alterna-
tively, compensate for its presence by the upregulation of
other genes whose products might at least partially pro-
vide enhanced structural stability to the skin, thereby
overriding the effect of the underlying mutation. Other
clinical trials are now underway to look at possible means
of enhancing wound healing, to include an ongoing one
assessing the potential efficacy of the topical application
of a small molecular weight protein, thymosin β4, to open
wounds [84].
Prognosis
The prognosis of EB is highly dependent on the subtype
of disease that is present. Most EB patients, particularly
those with EBS and DDEB, have normal life expectancies,
but significant morbidity may complicate some. In con-
trast, patients with JEB, most notably those with JEB-H,
are at major risk of death during the first few years of life,
and patients with RDEB, particularly those with severe
generalized RDEB, are at risk of death on or after young
adulthood from metastatic squamous cell carcinoma.
Unresolved questions
With rare exceptions, the underlying molecular cause of
nearly every EB subtype has now been elucidated. Using
such data, both postnatal and prenatal diagnoses are now
possible for most clinical situations.
It is clear, however, that some patients with identical
mutations may have vastly different clinical phenotypes
from others, suggesting the likely presence of other fac-
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now underway in several laboratories to search for possi-
ble modifier genes which might contribute to the overall
clinical severity within some of these EB subtypes and
might better explain the range of clinical phenotypes
which is observed within individual EB subtypes.
The remarkably high frequency with which squamous
cell carcinomas arise in RDEB, as well as the risk of
metastasis and death following wide surgical excision of
the primary tumors, is essentially unique. Inexplicably
these tumors act in a very biologically aggressive way
despite being usually very well differentiated histologi-
cally. Several leading EB research groups, therefore, are
now focusing their efforts on trying to determine why
RDEB-associated squamous cell carcinomas differ so
drastically in their behavior from those seen in the nor-
mal adult population, with the hope that a better under-
standing of the biology of these tumors in RDEB may
result in more successful treatments or more effective
means of prevention.
It is still unknown whether gene replacement will ulti-
mately become a realistic therapeutic modality, although
in vitro cell and in vivo animal studies continue to look
promising. It is also as yet unknown whether stem cell
transplantation, or implantation of viable allogeneic
fibroblasts into the skin of patients with RDEB, might
Table 6: Differential diagnosis of inherited EB (in neonates and small children) *
Inherited or congenital disorders
Epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma)







AEC syndrome (Hay-Wells syndrome)
Congenital absence of skin (cutis aplasia)











Staphylococcal scalded skin syndrome
Bullous impetigo
Other diseases or conditions
Bullous mastocytosis
Traumatic blisters (sucking; other)
* modified from Fine JD et al, 2000 [5]
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Page 15 of 17provide significant longterm clinical benefit and also be
safely administered.
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